Article review: The Case for Pembrolizumab TDM: From Multicenter Evidence to Clinical Action

This document brings together the clinical findings of the BLI-O multicenter study — the first real-world evidence to demonstrate that a single pembrolizumab plasma measurement after cycle 1 independently predicts survival in metastatic NSCLC — with a strategic assessment of what this evidence means for laboratory adoption, clinical practice, and the competitive positioning of the SHIKARI® PEM-FD-KEY ELISA platform.

Click here to view the article review

matrix@matriksbiotek.com info@matriksbiotek.com www.matriksbiotek.com

Matrix Biotek SL is the EU HQ (Barcelona, Spain) of Matriks Biotek Co., Ankara Türkiye.